This report presents the results of the first external quality assurance (EQA) scheme for B. pertussis antimicrobial susceptibility testing by ECDC as part of the European Reference Laboratory Network for Pertussis (ERLNPert-Net) consortium.
This report presents the results of the first external quality assessment (EQA) scheme for Bordetella pertussis vaccine antigen expression, pertactin (PRN), pertussis toxin (PT) and filamentous haemagglutinin (FHA) by the European Centre for Disease Prevention and Control (ECDC) as part of the European Reference Laboratory Network for Pertussis (ERLNPert-Net) activities.
This evidence brief summarises key issues and priorities for action in Europe and Central Asia on PrEP. It is largely based on data collected between February and August 2022.
This guidance document includes an updated summary of diagnostic PCR and serology together with detailed information on isolation, culture, identification and epidemiological typing of B. pertussis to help users choose the best methods within the local technical and financial provisions.
In 2021, 2 268 confirmed cases of listeriosis were reported by 30 EU/EEA Member States. The EU/EEA notification rate was 0.51 per 100 000 population. Germany, France, and Italy had the highest numbers of reported cases (560, 435 and 241, respectively), corresponding to 54.5% of all cases reported in the EU/EEA. The highest incidence rates were observed in Iceland, Finland, and Denmark. Figure 1 illustrates the country-specific age-standardised rates per 100 000 population.